Diadem Presents Data at 2023 AAIC® Showing Its AlzoSure® Blood Test Can Identify Patients at High Risk of Significant Cognitive Decline Due to Alzheimer's Disease

—Data from 479-Patient Study Confirms Strong Prognostic Utility of AlzoSure® Predict for Identifying Whether or Not Individuals Will Experience a Significant...

Related Keywords

Australia ,Milan ,Lombardia ,Italy ,Amsterdam ,Noord Holland ,Netherlands ,Australian ,Christopher Fowler ,Leander Van Neste ,Daniela Uberti ,Simona Piccirella ,Paul Kinnon ,Jurgen Fripp ,Sam Agus ,Barbara Lindheim ,Jamesd Doecke ,University Of Brescia ,Drug Research ,Alzheimer Association International Conference ,Us Food Drug Administration ,Patient Study Confirms Strong Prognostic Utility ,Identifying Whether ,Not Individuals Will Experience ,Significant Cognitive Decline ,Year Timeframe ,Will Develop ,Predict Can Facilitate Access ,Effective Treatment ,At Risk Patients ,Help Accelerate New Drug Research ,Diadem Anticipates ,Predict Will Be Commercially Available ,Association International ,Australian Imaging ,Breakthrough Device ,Drug Administration ,Colinl Masters ,Diadem Spa ,